Risk factors for suicide behaviors in the observational schizophrenia outpatient health outcomes (SOHO) study by unknown
Brugnoli et al. BMC Psychiatry 2012, 12:83
http://www.biomedcentral.com/1471-244X/12/83RESEARCH ARTICLE Open AccessRisk factors for suicide behaviors in the
observational schizophrenia outpatient health
outcomes (SOHO) study
Roberto Brugnoli1, Diego Novick2, Josep Maria Haro3, Andrea Rossi4, Marco Bortolomasi5, Sonia Frediani4 and
Giuseppe Borgherini6,7*Abstract
Background: To identify risk factors for suicide using data from a large, 3-year, multinational follow-up study of
schizophrenia (SOHO study).
Methods: Baseline characteristics of 8,871 adult patients with schizophrenia were included in a logistic regression
post-hoc analysis comparing patients who attempted and/or committed suicide during the study with those who
did not.
Results: 384 (4.3%) patients attempted or committed suicide. Completed suicides were 27 (0.3%). The significant
risk factors for suicide behaviors were previous suicidality, depressive symptoms, prolactin-related adverse events,
male gender and history of hospitalization for schizophrenia.
Conclusions: In view of the observational design of the study and the post-hoc nature of the analysis, the
identified risk factors should be confirmed by ad-hoc specifically designed studies.
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One of the most important causes of death among
patients with schizophrenia is suicide [1]. It has been
established that the risk of suicide is more than 8
times higher among patients with schizophrenia than
in the general population [2]. About 20 to 40% of
patients with schizophrenia make suicide attempts in
their lifetime and around 5% die by their own hand
[3]. The lifetime suicide attempt rate in schizophrenia
is lower than that in major depressive disorder [3], but
attempts are more dangerous, resulting in physical
harm significantly more often (44% vs 16%) [4]. Suc-
cessful lifetime suicide rates in schizophrenia seem to
vary considerably from country to country: they have
been reported to be approx 20–30:100,000 in Denmark
[5] versus 67:100,000 in China [6].* Correspondence: f.cavagnis@hotmail.it
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reproduction in any medium, provided the orA major hurdle in the prevention of suicide in schizo-
phrenia is the difficulty in evaluating the risk of suicidal
behaviors, as suicide in this patient population usually is
the result of a sudden, impulsive act that makes the
traditional assessment methods based on rating scales
and interviews of little use [7].
The current approach to the issue of suicide in schizo-
phrenia rests on antipsychotic treatment, preferentially
clozapine, in view of the efficacy it has proved to possess
in controlling suicidal behavior in the International Sui-
cide Prevention Trial (InterSePT) trial [8], and on the
identification of risk factors and the implementation of
preventive measures in high risk patients. At present,
there is a general consensus that youth (adolescents and
young adults), male gender, Caucasian race, unmarried
status, good premorbid function, post-psychotic depres-
sion and history of substance abuse and/or suicide
attempts are risk factors for suicide behaviors in patients
with schizophrenia [1].
The issue of the importance of the endocrine-related
adverse events of antipyschotic treatment has recentlyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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associated with distressing adverse events, such as sexual
dysfunction, amenorrhoea and galactorrhoea [9].
It is believed that such adverse events may influence
adherence to antipsychotic treatment, which is notori-
ously low in schizophrenia [10,11].
The Schizophrenia Outpatient Health Outcomes
(SOHO) study was a prospective, observational study
conducted in 10 European countries, which included
more than 10,000 outpatients who were initiating or
changing antipsychotic medication for the treatment of
schizophrenia [12-15].
Aim of the study
To identify risk factors for suicide behavior, we decided
to compare the baseline characteristics of the patients
who attempted or committed suicide over a 3-year
follow-up in the SOHO study with those patients who
did not.
Methods
These analyses are based on the SOHO study data, a
three-year, prospective, observational study of the health
outcomes of patients with schizophrenia. A total of
10,972 adult outpatients with a diagnosis of schizophre-
nia were recruited by psychiatrists in 10 European coun-
tries (Denmark, France, Germany, Greece, Ireland, Italy,
The Netherlands, Portugal, Spain, UK) from 1 Septem-
ber 2000 to 31 December 2001. Inclusion criteria were:
initiating or changing antipsychotic medication for the
treatment of schizophrenia; presenting within the nor-
mal course of care in the out-patient setting or in the
hospital when admission was planned for the initiation
of antipsychotic medication and discharge planned
within 2 weeks; at least 18 years of age; and not partici-
pating in an interventional study. Patients were included
regardless of the reason for treatment change (e.g. lack
of response, side-effects, etc.) and regardless of whether
an antipsychotic drug was being initiated as a replace-
ment for a previous medication, was an addition to
existing treatment, or was being initiated for the first
time or after a period of no treatment. The study was
designed to provide two patient cohorts of approxi-
mately equal size: i) patients who initiated therapy with
or changed to Olz; and ii) patients who initiated therapy
with or changed to a non-Olz antipsychotic. To achieve
approximately equal numbers in the Olz and non-Olz
groups, different sample fractions entered each cohort.
This resulted in a stratified sample, with the Olz group
as the over-sampled stratum. In most countries, enrol-
ment was conducted in a systematic alternating order;
the first patient was recruited into the Olz cohort, the
second patient into the non-Olz cohort, etc. Effort was
made to avoid interference with clinical practice.Investigators were instructed to make treatment deci-
sions independent of the study and then evaluate
whether patients were eligible for inclusion based on
entry criteria and the alternating structure of enrolment;
recruitment period was purposely very long and no
minimum number of cases was required by investigator.
The study was observational, so the protocol did not
provide any instructions regarding treatment or patient
management. Outcome data were collected 3 months
after baseline and thereafter every 6 months for 3 years.
The SOHO study was approved in all countries either
at the site, regional or national level, depending on the
country’s regulations and participating sites in each of
the countries. All patients gave at least oral informed
consent [13].
The baseline data collected included demographic and
social information, medical and psychiatric history, body
mass index (BMI), severity of symptoms rated using the
Clinical Global Impression-Schizophrenia scale dimen-
sions (CGI-SCH), namely overall, positive, negative, de-
pressive and cognitive symptom scores [16,17]. The CGI-
SCH scale was physician rated with values ranging from
1 (not ill) to 7 (among the most severely ill patients).
Number of suicide attempts from the previous data col-
lection was recorded by the investigator by answering the
question: How many times has the patient attempted sui-
cide since the last data collection. Completed suicides
were collected in the patient discontinuation form.
Patients with no missing data related to history of sui-
cide attempts and known medications at baseline and at
least one post-baseline visit were included in this analysis.
The comparison was made between the patients who,
over the 3-year follow-up, had attempted suicide at least
once or had committed suicide and those who had never
made a suicide attempt. Baseline characteristics were
analyzed descriptively. A comparison between patients
who attempted suicide and those who committed suicide
and between patients included in the analysis and those
not was also performed. A logistic regression model for
the outcome suicide attempt over follow-up was con-
ducted, including the following baseline covariates as in-
dependent variables: sex, age, age at first treatment
contact for schizophrenia, CGI-SCH dimensions (posi-
tive, negative, cognitive, depressive, overall), hospital ad-
mission previous to baseline, body mass index (BMI),
history of suicide attempts before baseline (none, one,
two or more), suicide attempts in the 6 months before
baseline (none, one, two or more), paid work, social con-
tacts in the previous 4 weeks, concomitant medications,
presence of extrapyramidal symptoms (EPS), tardive dys-
tonia (TD), sexual-related adverse events and adherence
to medications.
The rationale, methods and recruitment of the SOHO
study have been described in further detail elsewhere
Table 1 Demography, medical history, baseline data and








Demographic data and medical history
Age (years)mean ± SD 40.1 ± 13.1 38.6 ± 11.8
Male gender (%pat) 57.8% 59.1%
Employment (% pat) 19.7% 17.0%
Social contacts in the previous
4 weeks (% pat)
32.5% 36.8%
Time since first contact (years) 11.4 ± 11.0 11.2 ± 10.2
mean ± SD
Age at first contact (years) 28.8 ± 10.6 27.4 ± 10.0
mean ± SD
History of attempts (% pat) 23.5% 63.0%











Baseline characteristics* (mean± SD)
Overall symptom score 4.4 ± 1.0 4.5 ± 1.0
Positive symptom score 3.8 ± 1.4 3.9 ± 1.4
Negative symptom score 4.1 ± 1.3 4.2 ± 1.3
Depressive symptom score 3.4 ± 1.3 3.9 ± 1.4
Cognitive symptom score 3.8 ± 1.3 3.9 ± 1.3
BMI 26.2 ± 4.9 26.0 ± 4.8
Adverse events (% pat)
Extrapyramidal symptoms 37.4% 41.7%
Tardive dyskinesia 9.1% 12.4%





BMI body mass index; Pat patients.
* These data are expressed as mean ± SD and represent CGI-SCH scores.
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[14,15,18].
Results
Out of the 10,972 patients who were recruited (10,218
with available data), a total of 8,871 patients (86.9%)
were included in this analysis. 2,505 of these patients
dropped out of the study over 3 years: 8,115 completed
one year of observation, 7,271 two years and 6,366 three
years of observation. The analysis of patients included in
the analysis and those not included showed that those
excluded had a higher frequency of lifetime suicide
attempts (32% in the patients excluded from the analysis
versus 25% in those included) and a history of
hospitalization in the previous 6 months before the
study (51% in the patients not included in the analysis
versus 31% in those included).
A total of 384 (4.3%) patients attempted at least once
or committed suicide in the 3 years of the SOHO
study. Completed suicides were 27 (0.3%). Ninety-eight
patients dropped out of the study after a suicide at-
tempt (1.1%). Most of these patients attempted suicide
only once (n = 262 - 3.0%) or twice (n = 50 - 0.6%). The
suicide attempt rate was stable throughout the first
2.5 years (0.9-1.0%) and then diminished slightly in the
last six months (0.8%).
Descriptive analysis
There were no significant differences between patients
with and without suicide behaviors and in terms of age,
gender, occupational status, age at first treatment con-
tact for schizophrenia, time since onset and social activ-
ities in the last 4 weeks (Table 1).
A history of suicidal attempts and recent attempts in
the last 6 months were much more common among
patients with suicide behaviors: nearly three times as
many had attempted suicide in the past and nearly 7
times as many had made their attempts in the last
6 months. Also, a history of hospitalizations on account
of schizophrenia was more common amongst patients
with suicide behaviors (+56.4%). Depressive symptoms
were more severe among patients with suicide behaviors
(on average +0.5 points equivalent to a mean increase by
14.7%). Patients who attempted or committed suicide
were more likely to be taking antidepressants, anxioly-
tics/hypnotics and/or a mood stabilizer (Table 1).
The prevalence of adverse events was consistently
higher in patients with suicide behaviors compared to
patients without (Table 1). The phenomenon was par-
ticularly marked for prolactin-related adverse events,
namely amenorrhea (+64%), galactorrhea (+163%) and
gynecomastia (+200%).
The results are similar when excluding patients who
completed suicide from the analysis. The comparison ofthe patients who completed suicide versus those who
did not was limited by the low number of cases. The
only statistically significant difference is a higher propor-
tion of males (81% versus 58%).Logistic regression
The logistic regression model for the outcome suicide
behaviors (attempt or completed suicide) over the
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factors for suicide behaviors (Table 2): a lifetime history
of suicide, suicide attempts in the last 6 months,
prolactin-related adverse events, male gender, history of
hospitalization for schizophrenia, CGI depression score.
Age (years) and antipsychotic treatment adherence were
not risk factors for suicide attempts. Most of the patients
who presented prolactin-related adverse events were fe-
male (84% of the patients with those adverse events were
female versus 36% in the rest of the sample). There was
no significant interaction between prolactin-related ad-
verse events and gender, as regards suicide attempts. The
results are similar when excluding patients who com-
pleted suicide from the analysis. A further sensitivity ana-
lysis was conducted by also including in the analysis the
patients with unknown treatment at the baseline visit
and those with missing information about suicide
attempts at baseline. In the latter case, we have imputed
a “0”, the most frequent value, as number of suicide
attempts. The results from this model were very similar
to those described here.Discussion
The comparison of the characteristics of patients with
schizophrenia with and without suicide behaviors in this
large observational study, which included more than
10,000 patients in 10 European countries, has identified
a number of significant risk factors for suicide behaviors
(attempts or completed suicide): history of suicide
attempts, prolactin-related adverse events, male gender,
history of hospitalization for schizophrenia, indicated
both by CGI depression score. Age and compliance toTable 2 Logistic regression model for factors associated
to suicide behaviors (attempts or completed suicide) over
the follow-up period
OR (95% CI) p value
Age 0.995 (0.985, 1.005) 0.3418
Sex, male 1.614 (1.203, 2.166) 0.0014
CGI-SCH depressive symptoms 1.158 (1.058, 1.268) 0.0015
Hospital admission for schizophrenia 1.38 (1.08, 1.763) 0.0099
Suicide attempts in previous
6 months (1 versus 0)
2.083 (1.462, 2.968) <.0001
Suicide attempts in previous 6 months
(2 or more versus 0)
3.719 (1.852, 7.466) 0.0002
Suicide attempts ever (1 versus 0) 2.35 (1.696, 3.255) <.0001
Suicide attempts ever
(2 or more versus 0)
5.223 (3.913, 6.971) <.0001
Prolactin-related side effects 2.019 (1.391, 2.929) 0.0002
Complies with medication
(always versus never)
0.823 (0.496, 1.366) 0.4514
CGI-SCH: Clinical Global Impression-Schizophrenia Scale.treatment, on the contrary, did not result to be risk fac-
tors for suicide.
These results are consistent with previous studies on
the subject, which have already identified history of sui-
cide attempts, male gender and depression as risk factors
for suicide [1]. The only exception is age, as previous
studies identified young age as a risk factor, whereas age
in general did not result to be involved in this study. The
comparison of the patients who completed suicide with
those who did not was limited given the low number of
cases. However, male gender was the only significant dif-
ference between those who made a suicide attempt and
those who completed suicide.
To our knowledge, this is the first time that
prolactin-related adverse events (gynecomastia, galac-
torrhrea, amenorrhea) are included amongst the risk
factors for suicide. Depression, anxiety and hostility
have been repeatedly reported to be more frequent in
women with hyperprolactinemia. Fava et al. [16] found
that women with hyperprolactinemic amenorrhea pro-
vided higher self-ratings of these symptoms than both,
women with amenorrhea who had normal levels of pro-
lactin and women with regular menstrual cycles. Buck-
man [19] reported similar mood symptoms in response
to elevated prolactin in healthy women. Kellner et al.
[20] reported that depression, anxiety and hostility
scores in hyperprolactinemic women were similar to
those of psychiatric patients and suggested that prolac-
tin induces dysphoric states in its own right. However,
the direct impact of increased prolactin on mood and
behavior in men is still unclear.
Four relevant limitations should be highlighted in this
study. First, this is a post-hoc analysis of the SOHO pa-
tient data which included patients who were changed
antipsychotic treatment for clinical reasons and are thus
not representative of all patients with schizophrenia;
moreover, type of antipsychotic medication was not
included in the analysis Second, we have not measured
prolactin levels, but in SOHO we have assessed adverse
events which are potentially related to elevated prolactin
levels. Additionally, sexually related adverse events may
have multiple causes [21]. Third, suicidal behavior is
based on the psychiatrist report using one single ques-
tion which may be variable and have low reliability.
However, we think this bias will be non differential and
can rarely create spurious relationships as the ones
reported. Finally, patients not included in the analysis
because had missing data or were lost to follow-up had
somewhat higher frequency of lifetime suicide attempts.
Conclusions
This study has provided further support to known risk
factors for suicide in patients with schizophrenia, such as
history of suicide attempts, male gender and depression,
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adverse events. Further investigations are warranted to
clarify the relationship between prolactine related ad-
verse events and risk of suicide.
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Significant outcomes
The rate of patients who attempted or committed suicide in a 3-year
observational study on 8,871 evaluable outpatients with schizophrenia in 10
European countries was fairly low: 4.3%. Completed suicides were 0.3%.
The significant risk factors for suicide behaviors that were identified were:
history of suicide attempts, male gender, depressive symptoms, history of
hospitalization for schizophrenia and prolactin-related adverse events.
To our knowledge, this is the first study to identify prolactin-related adverse
events, namely amenorrhea, galactorrhea and gynecomastia, as risk factors
for suicide in schizophrenia. Additional investigations are needed to confirm
that these are indeed.
Limitations
The results derive from a post-hoc analysis of data collected during an
observational trial not designed to specifically evaluate factors predicting
suicide.
Prolactine levels were not measured.
The study only included patients who initiated or changed antipsychotic
medication treatment during outpatient treatment. Type of antipsychotic
medication was not included in the analysis.
Suicidal behavior is based on the psychiatrist report using one single
question which may be variable and have low reliability.
Patients not included in the analysis because had missing data or were lost
to follow-up, had somewhat higher frequency of lifetime suicide attempts.
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